Donald Weaver, MD, PhD, FRCPC, FCAHS

Achilles Demetriou, MD (Deceased)

The late Dr. Achilles Demetriou was University Hospitals’ first executive vice president and chief operation officer. He helped launch The Harrington Project and helped Dr. Stamler hire Baiju Shah to lead BioMotiv. Achilles was an exemplar of the physician-scientist that The Harrington Project intended to support. He was an acclaimed surgeon and researcher, and his passion was around helping patients and improving the standard of care.

David U’Prichard, PhD (Deceased)

The late Dr. David U’Prichard held an instrumental role in The Harrington Project for Discovery & Development by building world-class drug development capability and leading a search for new medicines. His career spanned academic research, biotech, pharma company leadership, venture capital, and extensive experience on the boards of public and private US, UK, European and Indian companies. After Jonathan convinced Dr. U’Prichard to join the BioMotiv team, David quickly mobilized his network of pharma leaders to assist Harrington Discovery Institute, and tapped other colleagues who shared his commitment to drug development to join the BioMotiv Advisory Board.

Daniel Simon, MD

As the Director of the UH Harrington Heart & Vascular Institute in 2009, Dr. Dan Simon recruited Jonathan Stamler from Duke University to University Hospitals. With his close relationship to the Harrington family and his belief in the vision for Harrington Discovery Institute and The Harrington Project, Dan quickly became a staunch supporter. His sponsorship continued as he was promoted to increasing levels of responsibility within the UH system, including President of UH Cleveland Medical Center and Chief Clinical & Scientific Officer for the entire health system.

Baiju Shah

Baiju Shah helped launch BioMotiv in 2012 as Harrington Discovery Institute’s first mission-driven, for-profit accelerator partner under The Harrington Project. Baiju was at that time President & CEO of BioEnterprise, a Cleveland-based business formation, recruitment, and acceleration initiative designed to grow healthcare companies and commercialize bioscience technologies. Baiju saw the need and opportunity that The Harrington Project was addressing and later signed on as BioMotiv’s CEO. He helped establish its unique business and investment platform that creates and operates biotech companies, providing capital, operating expertise and partnerships to speed the development of drug discoveries into medicines.